Q-omics provides the consensus-scored ZCCHC10 profile across patient tissues and cancer cell-line models. ZCCHC10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZCCHC10 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, ZCCHC10 RNA expression shows 19,272 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, LIHC, and ACC as cancer lineages where ZCCHC10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZCCHC10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZCCHC10 survival associations across molecular data types. ZCCHC10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZCCHC10 RNA expression–survival associations across cancer types. High ZCCHC10 expression shows unfavorable associations in HNSC, UVM, LIHC, SCLC and KICH, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZCCHC10 RNA expression.
This table summarizes ZCCHC10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZCCHC10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZCCHC10 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, KIRC, BRCA and HNSC. The LIHC box plot shows higher ZCCHC10 RNA expression in tumor versus normal tissue (log2 FC = +0.859, t-test p < 0.001).
This table shows molecular features associated with ZCCHC10 in patient tissues and cancer cell lines. In patient samples, ZCCHC10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZCCHC10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
